| Year |
Citation |
Score |
| 2023 |
Powis G, Meuillet EJ, Indarte M, Booher G, Kirkpatrick L. Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 165: 115024. PMID 37399719 DOI: 10.1016/j.biopha.2023.115024 |
0.322 |
|
| 2021 |
Jeung HC, Delaney R, Aleshin A, Indarte M, Correa RG, Bankston LA, Layng FIAL, Ahmed Z, Wistuba I, Yao Y, Duenas DG, Zhang S, Meuillet EJ, Marassi F, Liddington RC, et al. PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer. Experimental Cell Research. 112930. PMID 34800542 DOI: 10.1016/j.yexcr.2021.112930 |
0.397 |
|
| 2019 |
Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, et al. Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors. Cancer Research. 79: 5457. PMID 31615811 DOI: 10.1158/0008-5472.Can-19-2586 |
0.4 |
|
| 2019 |
Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, et al. An inhibitor of the pleckstrin homology domain of CNK1 selectively blocks the growth of mutant KRAS cells and tumors. Cancer Research. PMID 31040156 DOI: 10.1158/0008-5472.Can-18-2372 |
0.55 |
|
| 2017 |
Somlyai G, Collins TQ, Meuillet EJ, Hitendra P, D'Agostino DP, Boros LG. Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma. Oncotarget. PMID 28418852 DOI: 10.18632/Oncotarget.16238 |
0.344 |
|
| 2016 |
Kobes JE, Daryaei I, Howison CM, Bontrager JG, Sirianni RW, Meuillet EJ, Pagel MD. Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor. Pancreas. PMID 26918875 DOI: 10.1097/Mpa.0000000000000607 |
0.376 |
|
| 2016 |
Boros LG, D'Agostino DP, Katz HE, Roth JP, Meuillet EJ, Somlyai G. Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle. Medical Hypotheses. 87: 69-74. PMID 26826644 DOI: 10.1016/J.Mehy.2015.11.016 |
0.347 |
|
| 2015 |
Nakanishi M, Perret C, Meuillet EJ, Rosenberg DW. Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis. Carcinogenesis. 36: 478-86. PMID 25634334 DOI: 10.1093/Carcin/Bgv004 |
0.367 |
|
| 2015 |
Chen L, Du-Cuny L, Moses S, Dumas S, Song Z, Rezaeian AH, Lin HK, Meuillet EJ, Zhang S. Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells. Plos Computational Biology. 11: e1004021. PMID 25569504 DOI: 10.1371/Journal.Pcbi.1004021 |
0.767 |
|
| 2014 |
Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ. Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. International Journal of Nanomedicine. 9: 5653-65. PMID 25516710 DOI: 10.2147/Ijn.S68511 |
0.474 |
|
| 2014 |
Cantoria MJ, Boros LG, Meuillet EJ. Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells. Metabolomics : Official Journal of the Metabolomic Society. 10: 91-104. PMID 24482631 DOI: 10.1007/S11306-013-0555-4 |
0.766 |
|
| 2014 |
Cantoria MJ, Boros LG, Patel H, Han H, Ignatenko N, Meuillet EJ. Abstract 1434: Metformin-induced metabolic changes are k-ras-dependent in animal models of pancreatic cancer Cancer Research. 74: 1434-1434. DOI: 10.1158/1538-7445.Am2014-1434 |
0.766 |
|
| 2014 |
Boros LG, Meuillet EJ, Somlyai I, Jancsó G, Jákli G, Krempels K, Puskás LG, Nagy IL, Molnár M, Laderoute KR, Thompson PA, Somlyai G. Abstract 1426: Fumarate hydratase and deuterium depletion control oncogenesis via NADPH-dependent reductive synthesis: mitochondrial matrix water, DNA deuteration and epigenetic events Cancer Research. 74: 1426-1426. DOI: 10.1158/1538-7445.Am2014-1426 |
0.332 |
|
| 2013 |
Norberg JK, Sells E, Chang HH, Alla SR, Zhang S, Meuillet EJ. Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂. Pharmaceutical Patent Analyst. 2: 265-88. PMID 24237030 DOI: 10.4155/Ppa.12.90 |
0.573 |
|
| 2013 |
Medda F, Sells E, Chang HH, Dietrich J, Chappeta S, Smith B, Gokhale V, Meuillet EJ, Hulme C. Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells. Bioorganic & Medicinal Chemistry Letters. 23: 528-31. PMID 23237838 DOI: 10.1016/J.Bmcl.2012.11.030 |
0.627 |
|
| 2013 |
Meuillet EJ, Moses SA, Jandova J, Mash EA, Zhang S. Abstract 5563: Targeting the PH domain of TIAM1 to inhibit prostate cancer metastasis. Cancer Research. 73: 5563-5563. DOI: 10.1158/1538-7445.Am2013-5563 |
0.758 |
|
| 2013 |
Cantoria M, Boros L, Meuillet E. Metformin inhibits the TCA cycle and fatty acid synthesis in MIAPaCa-2 pancreatic cancer cells Pancreatology. 13: e18. DOI: 10.1016/J.Pan.2012.12.115 |
0.776 |
|
| 2012 |
Stephen RM, Pagel MD, Brown K, Baker AF, Meuillet EJ, Gillies RJ. Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Experimental Biology and Medicine (Maywood, N.J.). 237: 1273-80. PMID 23239438 DOI: 10.1258/Ebm.2012.011326 |
0.403 |
|
| 2012 |
Jandova J, Beyer TE, Meuillet EJ, Watts GS. The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration. Cell Biochemistry and Function. 30: 687-95. PMID 22692860 DOI: 10.1002/Cbf.2853 |
0.362 |
|
| 2012 |
Smith B, Chang HH, Medda F, Gokhale V, Dietrich J, Davis A, Meuillet EJ, Hulme C. Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells. Bioorganic & Medicinal Chemistry Letters. 22: 3567-70. PMID 22516282 DOI: 10.1016/J.Bmcl.2012.03.013 |
0.633 |
|
| 2012 |
Chang HH, Song Z, Wisner L, Tripp T, Gokhale V, Meuillet EJ. Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers. Investigational New Drugs. 30: 1865-77. PMID 21931968 DOI: 10.1007/S10637-011-9748-8 |
0.681 |
|
| 2012 |
Meuillet EJ, Moses SA, Lucero-Acuna A, Guzman R, Jeffrey J, Pagel M. Abstract 3752: Nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumor growth Cancer Research. 72: 3752-3752. DOI: 10.1158/1538-7445.Am2012-3752 |
0.773 |
|
| 2012 |
Cantoria MJ, Dragovich T, Meuillet E. Abstract 3694: Role of the inflammatory response in pancreatic cancer treatment Cancer Research. 72: 3694-3694. DOI: 10.1158/1538-7445.Am2012-3694 |
0.759 |
|
| 2012 |
Beyer TE, Smith RM, Song Z, Gokhale V, Moses SA, Meuillet EJ. Abstract 2835: Discovery of novel inhibitors for ECT2 as a novel therapeutic strategy for lung cancer Cancer Research. 72: 2835-2835. DOI: 10.1158/1538-7445.Am2012-2835 |
0.756 |
|
| 2012 |
Sells E, Medda F, Chang H, Gokhale V, Hulme C, Meuillet EJ. Abstract 2834: Discovery of a novel class of prostaglandin e2 synthesis inhibitors with anti-tumor activity in colorectal cancer Cancer Research. 72: 2834-2834. DOI: 10.1158/1538-7445.Am2012-2834 |
0.681 |
|
| 2012 |
Dumas S, Du-Cuny L, Moses S, Song Z, Zhang S, Meuillet EJ. Abstract 2166: In silico identification and biological evaluation of potent small molecule inhibitors targeting GAB1 pleckstrin homology domain Cancer Research. 72: 2166-2166. DOI: 10.1158/1538-7445.Am2012-2166 |
0.777 |
|
| 2011 |
Chang HH, Meuillet EJ. Identification and development of mPGES-1 inhibitors: where we are at? Future Medicinal Chemistry. 3: 1909-34. PMID 22023034 DOI: 10.4155/Fmc.11.136 |
0.618 |
|
| 2011 |
Meuillet EJ. Novel inhibitors of AKT: Assessment of a different approach targeting the pleckstrin homology domain Current Medicinal Chemistry. 18: 2727-2742. PMID 21649580 DOI: 10.2174/092986711796011292 |
0.438 |
|
| 2011 |
Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA. Development of sulfonamide AKT PH domain inhibitors. Bioorganic & Medicinal Chemistry. 19: 2046-54. PMID 21353784 DOI: 10.1016/J.Bmc.2011.01.049 |
0.757 |
|
| 2011 |
Morrow JK, Du-Cuny L, Chen L, Meuillet EJ, Mash EA, Powis G, Zhang S. Recent development of anticancer therapeutics targeting Akt. Recent Patents On Anti-Cancer Drug Discovery. 6: 146-59. PMID 21110830 DOI: 10.2174/157489211793980079 |
0.448 |
|
| 2011 |
Meuillet EJ, Mash EA, Olsen E, Moses SA, Morgan SS. Abstract A242: A novel AKT inhibitor, PH427, prevents UVB-induced signaling in human squamous skin carcinomas. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A242 |
0.8 |
|
| 2011 |
Meuillet E, Moses S, Johnson J, Lemos R, Abdelmelek MF, Powis G, Kirkpatrick L. Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A213 |
0.465 |
|
| 2010 |
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Molecular Cancer Therapeutics. 9: 706-17. PMID 20197390 DOI: 10.1158/1535-7163.Mct-09-0985 |
0.779 |
|
| 2010 |
Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie. 92: 660-4. PMID 20159031 DOI: 10.1016/J.Biochi.2010.02.006 |
0.466 |
|
| 2010 |
Chang H, Song Z, Tripp T, Wisner L, Gokhale V, Hulme C, Meuillet EJ. Abstract 3565: Novel inhibitors of mPGES-1 exhibit anti-tumor activity in colorectal and lung cancers Cancer Research. 70: 3565-3565. DOI: 10.1158/1538-7445.Am10-3565 |
0.681 |
|
| 2010 |
Zhang S, Meuillet E, Powis G, Kirkpatrick DL. Abstract 1975: PHuDock®, a computational discovery and development platform for novel PH domain-binding agents, identifies a novel antitumor AKT/PDPK1 inhibitor, PHT- 427 Cancer Research. 70: 1975-1975. DOI: 10.1158/1538-7445.Am10-1975 |
0.606 |
|
| 2010 |
Moses SA, Song Z, Du-Cuny L, Powis G, Mash E, Zhang S, Meuillet EJ. Abstract 1559: Targeting the PH domain of Tiam-1 to inhibit breast cancer metastasis Cancer Research. 70: 1559-1559. DOI: 10.1158/1538-7445.Am10-1559 |
0.764 |
|
| 2009 |
Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorganic & Medicinal Chemistry. 17: 6983-92. PMID 19734051 DOI: 10.1016/J.Bmc.2009.08.022 |
0.734 |
|
| 2009 |
Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Research. 69: 5073-81. PMID 19491272 DOI: 10.1158/0008-5472.Can-08-3839 |
0.785 |
|
| 2009 |
Berggren M, Sittadjody S, Song Z, Samira JL, Burd R, Meuillet EJ. Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. Nutrition and Cancer. 61: 322-31. PMID 19373605 DOI: 10.1080/01635580802521338 |
0.436 |
|
| 2009 |
James BP, Staatz WD, Wilkinson ST, Meuillet E, Powis G. Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells. Free Radical Biology & Medicine. 46: 821-7. PMID 19135146 DOI: 10.1016/J.Freeradbiomed.2008.12.012 |
0.322 |
|
| 2009 |
Powis G, Moses SA, Zhang S, Du‐Cuny L, Song Z, Herbst R, Jacoby J, Kirkpatrick L, Mash E, Meuillet EJ. Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B139 |
0.776 |
|
| 2008 |
Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, ... ... Meuillet EJ, et al. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Molecular Cancer Therapeutics. 7: 2621-32. PMID 18790745 DOI: 10.1158/1535-7163.Mct-07-2276 |
0.768 |
|
| 2007 |
Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuillet E, Nelson MA. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Experimental Cell Research. 313: 2969-79. PMID 17631291 DOI: 10.1016/J.Yexcr.2007.06.004 |
0.419 |
|
| 2007 |
Song Z, Saghafi N, Gokhale V, Brabant M, Meuillet EJ. Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster. Experimental Cell Research. 313: 1161-71. PMID 17316609 DOI: 10.1016/J.Yexcr.2007.01.004 |
0.404 |
|
| 2004 |
Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncology Research. 14: 513-27. PMID 15559765 DOI: 10.3727/0965040042380487 |
0.51 |
|
| 2004 |
Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Archives of Biochemistry and Biophysics. 429: 123-33. PMID 15313215 DOI: 10.1016/J.Abb.2004.04.020 |
0.456 |
|
| 2004 |
Meuillet E, Stratton S, Prasad Cherukuri D, Goulet AC, Kagey J, Porterfield B, Nelson MA. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. Journal of Cellular Biochemistry. 91: 443-58. PMID 14755676 DOI: 10.1002/Jcb.10728 |
0.364 |
|
| 2003 |
Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ, Martinez JD. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Letters. 202: 43-51. PMID 14643025 DOI: 10.1016/J.Canlet.2003.07.006 |
0.36 |
|
| 2003 |
Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Molecular Cancer Therapeutics. 2: 389-99. PMID 12700283 |
0.384 |
|
| 2002 |
Miljan EA, Meuillet EJ, Mania-Farnell B, George D, Yamamoto H, Simon HG, Bremer EG. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. The Journal of Biological Chemistry. 277: 10108-13. PMID 11796728 DOI: 10.1074/Jbc.M111669200 |
0.367 |
|
| 2002 |
Ambrad A, Stea B, Martinez J, Mahadevan D, Falsey R, Kislin K, Meuillet E. ZD1839 (‘Iressa’) an EGFR tyrosine kinase inhibitor radiosensitizes glioblastoma multiforme by inhibition of a cell survival pathway International Journal of Radiation Oncology*Biology*Physics. 54: 95. DOI: 10.1016/S0360-3016(02)03220-0 |
0.373 |
|
| 2002 |
Sun H, Bapu Reddy G, George C, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. Synthesis and biological activity of 3-hydroxy(phosphono)methyl-bearing phosphatidylinositol ether lipid analogues Tetrahedron Letters. 43: 2835-2838. DOI: 10.1016/S0040-4039(02)00354-4 |
0.436 |
|
| 2001 |
Rong SB, Hu Y, Enyedy I, Powis G, Meuillet EJ, Wu X, Wang R, Wang S, Kozikowski AP. Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. Journal of Medicinal Chemistry. 44: 898-908. PMID 11300871 DOI: 10.1021/Jm000493I |
0.311 |
|
| 2001 |
Hu Y, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. 3-deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth Bioorganic and Medicinal Chemistry Letters. 11: 173-176. PMID 11206452 DOI: 10.1016/S0960-894X(00)00640-5 |
0.437 |
|
| 2001 |
Wang X, Rahman Z, Sun P, Meuillet E, George D, Bremer EG, Al-Qamari A, Paller AS. Ganglioside modulates ligand binding to the epidermal growth factor receptor. The Journal of Investigative Dermatology. 116: 69-76. PMID 11168800 DOI: 10.1046/J.1523-1747.2001.00222.X |
0.301 |
|
| 2000 |
Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. Journal of Medicinal Chemistry. 43: 3045-51. PMID 10956212 DOI: 10.1021/Jm000117Y |
0.494 |
|
| 2000 |
Meuillet EJ, Mania-Farnell B, George D, Inokuchi JI, Bremer EG. Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431 Experimental Cell Research. 256: 74-82. PMID 10739654 DOI: 10.1006/Excr.1999.4509 |
0.314 |
|
| 1999 |
Meuillet EJ, Wiernsperger N, Mania-Farnell B, Hubert P, Cremel G. Metformin modulates insulin receptor signaling in normal and cholesterol-treated human hepatoma cells (HepG2) European Journal of Pharmacology. 377: 241-252. PMID 10456437 DOI: 10.1016/S0014-2999(99)00386-6 |
0.318 |
|
| 1998 |
Meuillet EJ, Bremer EG. Growth factor receptors as targets for therapy in pediatric brain tumors Pediatric Neurosurgery. 29: 1-13. PMID 9755305 DOI: 10.1159/000028677 |
0.313 |
|
| 1997 |
Rebbaa A, Yamamoto H, Saito T, Meuillet E, Kim P, Kersey DS, Bremer EG, Taniguchi N, Moskal JR. Gene transfection-mediated overexpression of β1,4-N-acetylglucosamine bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function Journal of Biological Chemistry. 272: 9275-9279. PMID 9083062 DOI: 10.1074/Jbc.272.14.9275 |
0.31 |
|
| Show low-probability matches. |